Mergers & acquisitions
Now insiders say J&J has decided it is no longer interested.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
The company struck the cash-and-share deals to boost its presence in Europe.
News of the buy was tucked away in the company’s fourth-quarter financial report.
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Here are five possible acquisition targets to keep an eye on.
Employees of Juno received a surprise in their Monday morning emails.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
PRESS RELEASES